Development asset linked to Xynomic Pharmaceuticals in public FDA and regional records. Molecular target: Histone deacetylase.
- Target
- Histone deacetylase
- Mechanism
- Histone deacetylase inhibitor
pharma · Non Hodgkin Lymphoma
Xynomic Pharmaceuticals
Xynomic Pharmaceuticals drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Xynomic Pharmaceuticals pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Xynomic Pharmaceuticals drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.